| Similar Articles |
|---|
 |
Reason
March 2003
Jacob Sullum |
High Road Is marijuana a "gateway"?   |
Reason
March 2009
Jacob Sullum |
Briefly Noted: Pot Mythology "Marijuana is not anti-establishment because it's illegal," writes High Times Executive Editor David Bienenstock in his new book. "It's illegal because it's anti-establishment." |
Reason
Aug/Sep 2001
Jacob Sullum |
Bad Timing "The Drug War Worked Once. It Can Again." So read the headline above William J. Bennett's May 15 defense of drug czar nominee John Walters in The Wall Street Journal... |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
Chemistry World
November 2010 |
Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream? |
Chemistry World
March 2011 |
Column: In the pipeline Drug discovery is an inherently risky business. Derek Lowe tries to balance some of the risk equations |
The Motley Fool
March 4, 2010
Brian Orelli |
A Painless Drug Deal Bristol-Myers licenses pain drug from Allergan. |
The Motley Fool
July 30, 2010
Brian Orelli |
A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs. |
Reason
April 2006
Jacob Sullum |
Blow in the Wind Despite reports to the contrary, the dramatic increase in interdiction has not had a noticeable impact on cocaine use. In a national survey, the number of past-month cocaine users was almost exactly the same in 2004 as it was in 2002. |
Chemistry World
July 16, 2010
Matt Wilkinson |
Bittersweet victory for GSK's Avandia GlaxoSmithKline has received a muted 'thumbs up' from a US regulatory advisory panel for its much-maligned Type 2 diabetes drug Avandia (rosiglitazone), making it likely the US Food and Drug Administration will allow the UK-based pharma giant to continue selling the drug in the US. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
Reason
January 2004
Renee Moilanen |
Just Say No Again The old failures of new and improved anti-drug education |
The Motley Fool
March 31, 2011
Brian Orelli |
Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good. |
The Motley Fool
January 28, 2010
Brian Orelli |
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward. |
The Motley Fool
January 29, 2010
Brian Orelli |
How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years. |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
Salon.com
March 12, 2002
Janelle Brown |
Saying no to propaganda Critics say the government's new anti-drug campaign is reactionary and moralistic. Worse, it may not even work... |
The Motley Fool
May 20, 2010
Brian Orelli |
FDA Transparency! A Big Win for Investors The Food and Drug Administration has possibly just made things easier for investors. Let's just hope drug companies don't shoot it down. |
Reason
August 2002
Jacob Sullum |
Anti-Drug Anxiety Trouble at the propaganda mill: In May a study finding that government anti-drug propaganda has not reduced teenagers' drug use prompted sniping between the drug warriors who commission the messages and the admen who create them. |
Job Journal
November 9, 2003
Bob Rosner |
What Matters More Than Money? Smart managers use more than money to motivate workers. |
The Motley Fool
March 8, 2010
Brian Orelli |
Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting. |
Salon.com
July 27, 2000
Daniel Forbes |
Fighting "Cheech & Chong" medicine Did the White House drug office go too far in trying to stop the spread of medical marijuana initiatives? |
The Motley Fool
March 30, 2011
Sean Williams |
China Clamps Down on Drug Manufacturers These drug manufacturers could be feeling a pinch from new Chinese price caps. |
The Motley Fool
January 12, 2010
Dayana Yochim |
6 Ways to Score Cheap(er) Drugs Stop overpaying for the pills you have to pop with these simple ways to trim your prescription-drug tab. |
